Introduction {#S0001}
============

Hereditary medullary thyroid cancer (MTC) is typically one of the neoplasia characterizing Multiple Endocrine Neoplasia type 2 syndromes (MEN 2), but it is not a clinical manifestations of MEN 1 syndrome. Here we report on the case of a patient affected by MEN 1 syndrome who developed an MTC. A review of previously described cases in the English Literature was performed to verify what is currently known about this unusual association. A comprehensive research was run in PubMed (Medline) and Scopus as at 31st December 2019 using the keywords: "medullary thyroid cancer", "MEN 1", and "MEN 2". The "related articles" function was used to widen the search and all abstracts, studies, and citations retrieved were reviewed. To our knowledge, the present is the fourth case of this rare association reported so far.

Case Presentation {#S0002}
=================

A 60-year-old Caucasian woman was admitted in October 2018 for recurrent hyperparathyroidism in MEN 1 syndrome. This condition had been diagnosed in 2001 after the discovery of a small non-functioning neuroendocrine tumor (NF-NET) of the head of the pancreas, 1.5 cm in diameter, and primary hyperparathyroidism due to bilateral parathyroid hyperplasia. A subtotal parathyroidectomy was performed in the same year, and the patient's NF-NET was still being followed up. Genetic testing revealed a *MEN 1* gene mutation. Family screening with the same DNA test confirmed a sporadic MEN 1 syndrome, as no other family members were affected. No other more or less typical manifestations of MEN 1 were identified. The patient's remote medical history included carpal tunnel surgery and breast cancer treated with surgery and radiotherapy. She had no family history of thyroid disease, nor any risk factors for thyroid cancer apart from her age. Physical examination revealed no neck or lateral-cervical tenderness. The patient followed up routinely until 2018, when neck ultrasonography for relapsing hyperparathyroidism revealed an adenoma in the left inferior parathyroid, confirmed by technetium (99mTc) Sestamibi scintigraphy ([Figure 1](#F0001){ref-type="fig"}). Laboratory tests showed high serum parathyroid hormone (PTH) and calcium (Ca) levels: PTH: 153 ng/L (normal values 4.6--26.8); Ca: 2.67 mmol/L (normal values 2.1--2.55). The patient was therefore admitted to our Clinic and she underwent left inferior parathyroidectomy, extended to include the left thyroid lobe due to the presence of tenacious adhesions resulting from her previous cervical surgery. Intraoperative rapid assay showed that PTH levels dropped from 119 ng/L at the time of inducing anesthesia to 5 ng/L ten minutes after the removal of the mass. Macroscopically, the resected specimen comprised the left thyroid lobe (3.6 x 2.5 x 1 cm) with parathyroid tissue (maximal diameter 1.7 cm). Histological examination after fixing 4 μm sections from paraffin-embedded blocks in 10% buffered formalin and staining with hematoxylin and eosin identified showed: micro MTC (0.4 cm in diameter) associated with scant amyloid stroma in the thyroid gland and parathyroid adenoma consisting of clear cells and oxyphilic cells. On immunohistochemistry (Leica Bond system; Bond-III; Leica Microsystems, Milan, Italy), the medullary tumor showed positive reactions to Chromogranin A and carcinoembryonic antigen (CEA) and was slightly reactive to Calcitonin; Ki67 expression was low (\<5%) ([Figure 2A](#F0002){ref-type="fig"}--[D](#F0002){ref-type="fig"}). *RET* gene study on DNA from the tumor tissue revealed no somatic mutations in exons 10, 11, 13, 14, 15 or 16. Subsequent computed tomography (CT) of the neck, chest and abdomen identified no abnormalities. About 6 months later, in April 2019, the patient underwent total thyroidectomy. The pathologist only reported focal reactive C-cell hyperplasia of the thyroid. The postoperative course was uneventful, and the patient was discharged after three days. With a follow-up of 12 months, the patient is asymptomatic and has normal serum Ca, PTH and calcitonin levels.Figure 1MIBI-Technetium subtraction scintigraphy, with evidence of left inferior parathyroid tracer uptake.Figure 2Histopathology of resected medullary thyroid cancer (MTC). Microscopically, it revealed polygonal cells with pale cytoplasm surrounded by fibrosis, collagen and amyloid tissue. H&E staining, (**A**). On immunohistochemistry, MTC was positive for Chromogranin (**B**), and CEA (**C**), and slightly positive for calcitonin (**D**). Magnification 40x (**A**); 100x (**B**); 200x (**C** and **D**).

Discussion {#S0003}
==========

Multiple endocrine neoplasia type 1 (MEN 1) is a hereditary syndrome characterized by hyperplastic and neoplastic disorders mainly affecting the parathyroid, anterior pituitary and gastro-enteric and pancreatic endocrine tissues. It is caused by a *MEN 1* gene mutation in chromosome 11. A heterozygous germline mutation is identified in the *MEN 1* gene of most individuals with the syndrome. Somatic mutations and large deletions of the *MEN 1* locus and its surrounding region in chromosome 11, known as a loss of heterozygosity (LOH), are also found in MEN1-associated tumors.[@CIT0001] Medullary thyroid cancer (MTC) is a malignant tumor of the calcitonin-secreting para-follicular C-cells of the thyroid gland that is not among the variety of diseases associated with MEN 1 syndrome. Up to 25% of MTC are associated with pathogenic germinal variants on the *RET* proto-oncogene (locus 10q11.2) that cause familial MTC or multiple endocrine neoplasia type 2 (MEN 2).[@CIT0002] Consistently with the prominent role of *RET*, sporadic cases of MTC harbor a somatic *RET* mutation in a significant proportion of cases (43% to 65%), typically in exon 16 (codon 918).[@CIT0003] C-cell hyperplasia (CCH) should be considered a pre-neoplastic condition that leads to the development of MTC, and is commonly seen in patients with germline mutations in the *RET* oncogene. It is therefore important to obtain a precise pathological classification of CCH as either a pre-neoplastic or a merely reactive (physiological) process.[@CIT0004] MTC associated with MEN 1 is extremely rare: it has previously been reported only three times.[@CIT0005]--[@CIT0007] A summary of the previously published cases is given in [Table 1](#T0001){ref-type="table"}. There are essentially two possible explanations for this association: an inherited predisposition to MTC linked to the *MEN 1* gene; or a sporadic MTC developing in a patient with MEN 1 syndrome.Table 1Previously Published Cases, with Their Clinical and Genetic FeaturesAuthorM/FAgeMEN 1 LocalizationsMEN 1 SyndromeMTC Size (cm)LOH of *MEN 1* Gene*RET* MutationsBohacek[@CIT0005]F61PROLACTINOMA\
pNET\
PHPTFamilial1 cmNANAAranda[@CIT0006]F44Prolactinoma\
pNET\
PHPTFamilial2 cmYESNOCetani[@CIT0007]M42Prolactinoma\
pNET\
PHPTFamilial2 cmNOYESPresent caseF60pNET\
PHPTSporadic0.4 cmNANO[^1]

In 2014, Bohacek[@CIT0005] was the first to describe this combination of neoplasms in a 60-year-old Canadian woman. She was diagnosed with familial MEN 1 syndrome with a prolactinoma, a pancreatic neoplasm, and a parathyroid adenoma. She underwent total thyroidectomy for thyroid nodules many years after a first surgical procedure for uncontrolled hyperparathyroidism, and the final pathology report identified MTC. No genetic tests were carried out, so nobody knows whether this MTC was sporadic or related to MEN 1 syndrome. Aranda[@CIT0006] described a similar case two years later: a 44-year-old Spanish woman with familial MEN 1 syndrome and the same neuroendocrine neoplasms was incidentally found to have MTC during the histological analysis of her thyroid specimen. Genetic testing revealed LOH of the *MEN 1* gene in MTC, with no evidence of any *RET* mutation, suggesting that the MTC occurred as part of the MEN 1 syndrome. More recently, Cetani[@CIT0007] described a patient with familial MEN 1 syndrome who had a prolactinoma, a pancreatic neuroendocrine tumor, hyperparathyroidism and a simultaneous metastatic MTC. Unlike the case reported by Aranda et al, genetic testing on the parathyroid and pancreatic neoplasm revealed LOH in the *MEN 1* gene, but not in the MTC tissue. *RET* analysis on the MTC tissue revealed a point mutation in exon 16, meaning that this MTC cannot be a manifestation of MEN 1 syndrome, but an incidental, sporadic tumor.[@CIT0006]

Our patient had sporadic MEN 1 syndrome and genetic testing on her MTC tissue identified no *RET* mutation. Unfortunately, no analysis of LOH of the *MEN 1* gene locus was conducted, so a specific link between this patient's MTC and her MEN 1 syndrome cannot be ruled out completely.

To date, only the patient described by Aranda et al was certainly a case of MTC as a manifestation of LOH of the *MEN 1* gene.[@CIT0006] The other three cases, including ours, were probably incidental, sporadic cancers. That said, the thyroid gland could become a target to examine periodically in the follow-up of patients with MEN 1 syndrome. Serum calcitonin testing and neck ultrasonography could be performed at minimal expense to rule out any presence of MTC in these patients.
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